Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer

Oppenheimer raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $19 from $17 and keeps a Perform rating on the shares. The firm sees the Delaware court’s verdict in favor of Acadia as consistent with its expectations for Nuplazid intellectual property protection while removing a perceived overhang on the shares. The court specifically concluded that Acadia demonstrated by preponderance of evidence that Aurobindo infringes patent claims, the analyst tells investors in a research note. Opco now anticipates investor focus to reset back to key dynamics following the Q1 update and ahead of research and development day on June 25.

Confident Investing Starts Here:

• Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions

• Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on ACAD:

Disclaimer & DisclosureReport an Issue

• Acadia Pharmaceuticals price target raised to $30 from $27 at Needham

• ACADIA Pharmaceuticals: Buy Rating Affirmed Amid Legal Victory and Promising R&D Prospects

• District court finds Aurobindo infringes Acadia Pharmaceuticals patent claims

• Acadia Pharmaceuticals files to sell 43.58M shares of common stock for holders

• ACADIA Pharmaceuticals Reports Strong Q1 Earnings Growth